Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$204.93-0.6%$199.66$153.58▼$218.66$362.52B0.615.76 million shs9.25 million shsVRTXVertex Pharmaceuticals$483.49-0.3%$479.96$377.85▼$519.88$124.16B0.411.28 million shs987,547 shs10 Stocks Set to Soar in Spring 2025Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.56%+1.87%-3.00%+14.21%+13.40%VRTXVertex Pharmaceuticals-0.26%-3.36%+0.04%+19.16%+18.09%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.533 of 5 stars2.53.03.33.93.52.51.3VRTXVertex Pharmaceuticals3.9414 of 5 stars2.33.00.03.33.52.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.92Moderate Buy$211.453.18% UpsideVRTXVertex Pharmaceuticals 2.65Moderate Buy$509.175.31% UpsideCurrent Analyst Ratings BreakdownLatest VRTX and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$408.00 ➝ $420.003/31/2025VRTXVertex PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$555.00 ➝ $567.003/17/2025ABBVAbbVieErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/5/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.003/4/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.002/20/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$407.00 ➝ $408.002/11/2025VRTXVertex PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Hold$408.00 ➝ $424.002/11/2025VRTXVertex PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$460.00 ➝ $520.002/11/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$402.00 ➝ $407.002/11/2025VRTXVertex PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$435.00 ➝ $467.002/11/2025VRTXVertex PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$480.00 ➝ $480.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.44$15.15 per share13.53$1.90 per share107.86VRTXVertex Pharmaceuticals$11.02B11.27N/AN/A$63.90 per share7.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.4085.3914.661.627.59%296.28%12.65%4/25/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$2.20N/A27.612.11-4.86%-2.02%-1.49%5/5/2025 (Estimated)Latest VRTX and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/25/2025N/AABBVAbbVie$2.51N/AN/AN/A$12.91 billionN/A2/10/2025Q4 2024VRTXVertex Pharmaceuticals$3.99$3.54-$0.45$3.50$2.78 billionN/A1/31/2025Q4 24ABBVAbbVie$2.98$2.16-$0.82-$0.02$14.81 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.20%+6.04%273.33%53 YearsVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest VRTX and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025ABBVAbbViequarterly$1.643.4%4/15/20254/15/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie17.940.660.55VRTXVertex Pharmaceuticals0.012.692.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.08%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie50,0001.77 billion1.76 billionOptionableVRTXVertex Pharmaceuticals6,100256.79 million256.28 millionOptionableVRTX and ABBV HeadlinesRecent News About These CompaniesRoyal Bank of Canada Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $420.00April 3 at 1:49 AM | americanbankingnews.comIs Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?April 3 at 12:18 AM | finance.yahoo.comGroupama Asset Managment Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 2 at 7:07 AM | marketbeat.comTweedy Browne Co LLC Sells 12,969 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 2 at 6:54 AM | marketbeat.comGeode Capital Management LLC Sells 287,652 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 2 at 6:27 AM | marketbeat.comSchroder Investment Management Group Has $65.35 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 2 at 4:49 AM | marketbeat.comTrump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocksApril 1 at 2:01 PM | cnbc.comVRTX Provides Mixed Updates for Type 1 Diabetes Pipeline CandidatesApril 1 at 11:55 AM | zacks.comVertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $567.00 at Bank of AmericaApril 1 at 8:26 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Increased by B. Metzler seel. Sohn & Co. AGApril 1 at 6:57 AM | marketbeat.comColrain Capital LLC Acquires New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 1 at 6:50 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Reduced by Alliancebernstein L.P.April 1 at 6:31 AM | marketbeat.comAIA Group Ltd Cuts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 1 at 6:01 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Increased by Wellington Management Group LLPApril 1 at 5:53 AM | marketbeat.comBank of America Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $567.00April 1 at 2:29 AM | americanbankingnews.comClearbridge Investments LLC Has $745.34 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 31 at 7:20 AM | marketbeat.comJoseph Group Capital Management Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 31 at 6:31 AM | marketbeat.comCalifornia Public Employees Retirement System Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 31 at 6:24 AM | marketbeat.comAllstate Corp Makes New $3.07 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 31 at 5:11 AM | marketbeat.comBlair William & Co. IL Has $10.73 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 31 at 4:37 AM | marketbeat.comVertex Pharmaceuticals: Advancements in T1D Program and Strategic Focus on Innovative Therapies Justify Buy RatingMarch 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingAbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketBy Chris Markoch | March 23, 2025View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketVRTX and ABBV Company DescriptionsAbbVie NYSE:ABBV$204.93 -1.34 (-0.65%) Closing price 04/2/2025 03:58 PM EasternExtended Trading$205.05 +0.12 (+0.06%) As of 04/2/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Vertex Pharmaceuticals NASDAQ:VRTX$483.49 -1.25 (-0.26%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$470.22 -13.28 (-2.75%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
